In continuation of my update on Nilotinib
We know that, Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved for the treatment of chronic myelogenous leukemia
Now, researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug nilotinib, to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.....More...
Now, researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug nilotinib, to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.....More...
Cancer drug prevents build-up of toxic brain protein
Ref : http://hmg.oxfordjournals.org/content/early/2013/05/09/hmg.ddt192
Ref : http://hmg.oxfordjournals.org/content/early/2013/05/09/hmg.ddt192
